Articles related to HEALTHCARE ACCESS

Dr. Vanita Noronha from the Tata Memorial Centre in Mumbai emphasizes the need for rethinking drug dosing approaches for modern therapies like nivolumab, an immunotherapy. Ongoing and planned trials in India are exploring cost-effective alternative dosing regimens due to the prohibitive cost of standard-dose therapies. Dr. Vanita Noronha from the Tata Memorial Centre highlighted the role of factors such as pharmacokinetics, pharmacodynamics, receptor affinity, and drug elimination in determining drug dosing during a Q&A session with Clinical Advances in Hematology & Oncology. The traditional dosing approach does not apply to modern therapies like nivolumab, an immunotherapy that binds to the PD-1 protein. According to Dr. Noronha, the drug reaches receptor saturation at a low dose, and hence increasing dosage does not increase receptor binding. For nivolumab to be effective, 70-75% of the PD-1 receptor needs to be occupied, which occurs at a dose of 0.3 mg/kg, only a tenth of the usually administered dose of 3 mg/kg. Dr. Noronha further described a study published in the Journal of Clinical Oncology in 2023 on low-dose nivolumab in head and neck cancer. The study, conducted with Indian patients who cannot afford standard dosing, used a regimen of oral metronomic chemotherapy along with […]

Pfizer and Thermo Fisher Scientific have partnered to expand access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in over 30 countries across Latin America, Africa, the Middle East, and Asia. The collaboration aims to address the limited availability of advanced genomic testing in these regions. Local access to NGS testing can provide faster analysis of associated genes, enabling healthcare providers to select the most appropriate therapy for individual patients. Thermo Fisher will identify local laboratories that will use their NGS technology and ensure they meet industry standards, while Pfizer will explore ways to make NGS testing affordable and raise awareness among healthcare providers. The companies plan to expand geographically and extend testing to other types of cancer. The global burden of cancer is expected to rise significantly, with breast and lung cancer being the leading types responsible for millions of deaths worldwide. To improve treatment outcomes, the collaboration seeks to deliver precision insights to underserved patients through rapid NGS testing conducted in decentralized labs closer to where patients are treated. The program aims to provide tailored care for cancer patients worldwide, acknowledging that individualized approaches based on precise disease characteristics are often required. By adopting next-generation […]

The United States is currently experiencing a shortage of Adderall, a medication used to treat attention deficit disorder (ADD)/attention deficit hyperactivity disorder (ADHD) and narcolepsy. The FDA, in frequent communication with manufacturers, has not provided a clear timeline for when the shortage will be resolved. The shortage is attributed to various factors. The demand for Adderall has increased significantly, with a 10% rise in prescriptions filled in 2021 compared to the previous year. The US Drug Enforcement Agency’s efforts to combat prescription drug misuse have also played a role in limiting production. Furthermore, the pandemic led to the emergence of telemedicine startups, making it easier for individuals to obtain Adderall prescriptions, sometimes inaccurately. While waiting for the supply to be restored, healthcare professionals can consider alternative therapies such as dexmethylphenidate, methylphenidate, and dextroamphetamine.

Single-tablet regimen (STR) coverage under qualified health plans (QHPs) varies widely across the US. Although bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) coverage has grown over time, many QHPs in priority jurisdictions for the Ending the HIV Epidemic (EHE) have coinsurance requirements. Delay in QHP coverage and benefit design may hinder access to new antiretroviral treatment (ART) regimens.

The Organ Transplant and Procurement Network (OTPN) is set to undergo modernization and improvement after being criticized for lack of transparency, long waits, mishandling of organs, and the number of people who die on the waitlist each year. The Health Resources and Services Administration (HRSA) has launched the OTPN modernization project, which will focus on accountability. The current system is outdated and has been responsible for 70 deaths between 2010 and 2020, according to a 2022 senate report. The HRSA plans to take steps, such as creating a new dashboard, to provide transparency and better serve patients and their families. Additional modernization will focus on overhauling the operations of the OTPN system to ensure higher compliance and a greater focus on patient safety. Organ transplants and the OTPN disproportionately affect the Black community in the US. About 30% of the ONTP waitlist is Black Americans, and about 90% are waiting for kidney transplants. The HRSA’s plan hopes to address the inequality by improving accountability, transparency, and systems of organ retrieval and matching. The changes will benefit patients, and physicians might be able to see more of their patients receive the life-saving transplants they need.

For the first time, Uber Health users, including healthcare providers and health plans, will be able to manage prescription delivery from any pharmacy in their service area via the same platform they use to coordinate patient transportation. This launch allows providers to offer a comprehensive suite of care solutions that extend beyond the four walls of a clinic and is intended to improve patient experiences and health outcomes.